Erasca ERAS
NASDAQ ERAS
$16.15 -0.11 (-0.68%)
As of: Sep 4, 2026 · 12:51 PM EDT

Erasca (ERAS) Consolidated Net Income (2020 - 2026)

Erasca's (ERAS) quarterly Consolidated Net Income came in at -$860.7 million in Q1 2026, down 2218.06% YoY from $40.6 million in Q1 2025, and down 2423.74% on a QoQ basis from -$34.1 million in Q4 2025.

Analysis

Erasca (ERAS) Consolidated Net Income (2020 - 2026) Analysis & Trends

Erasca (ERAS) has 7 years of Consolidated Net Income data on file, last reported at -$860.7 million in Q1 2026.

  • Quarterly Consolidated Net Income fell 2218.06% year-over-year to -$860.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 267.67% YoY) and the FY2025 annual result came in at -$383.1 million, down 98.94% from the prior year.
  • Consolidated Net Income retreated to -$860.7 million in Q1 2026, from -$34.1 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$29.4 million in Q4 2023 to a low of -$860.7 million in Q1 2026.
  • A 5-year average of -$118.3 million and a median of -$55.7 million in 2025 frame the typical range for Consolidated Net Income.
  • Annual changes were most pronounced in 2023 — Consolidated Net Income surged 78.8% — and 2026, when it slumped 2218.06%.
  • Tracing ERAS's Consolidated Net Income over 5 years: stood at -$138.7 million in 2022, then surged by 78.8% to -$29.4 million in 2023, then dropped by 27.25% to -$37.4 million in 2024, then advanced by 8.84% to -$34.1 million in 2025, then tumbled by 2423.74% to -$860.7 million in 2026.
  • The last three Consolidated Net Income figures came in at -$860.7 million (Q1 2026), -$34.1 million (Q4 2025), and -$51.1 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Erasca 5.03 Bn 5.03 Bn - -44.08 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -44.08 Mn
Mar 31, 2026 -183.46 Mn
Dec 31, 2025 -29.04 Mn
Sep 30, 2025 -30.58 Mn
Jun 30, 2025 -33.88 Mn
Mar 31, 2025 -30.97 Mn
Dec 31, 2024 -30.43 Mn
Sep 30, 2024 -31.37 Mn
Jun 30, 2024 -63.20 Mn
Mar 31, 2024 -35.02 Mn
Dec 31, 2023 -29.70 Mn
Sep 30, 2023 -30.36 Mn
Jun 30, 2023 -31.78 Mn
Mar 31, 2023 -33.20 Mn
Dec 31, 2022 -135.25 Mn
Sep 30, 2022 -35.49 Mn
Jun 30, 2022 -35.61 Mn
Mar 31, 2022 -36.46 Mn
Dec 31, 2021 -30.97 Mn
Sep 30, 2021 -46.07 Mn